A Review of its Pharmacology and Therapeutic Potential in the Treatment of Schizophrenia

[1]  L. W. Thompson.  The dopamine hypothesis of schizophrenia. , 2009, Perspectives in psychiatric care.

[2]  E. Snoeck,et al.  Plasma protein binding of risperidone and its distribution in blood , 1994, Psychopharmacology.

[3]  J. Leysen,et al.  Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat , 1994, Psychopharmacology.

[4]  E. Klieser,et al.  Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: A double blind, randomized trial , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  R. Kerwin,et al.  Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone , 1993, British Journal of Psychiatry.

[6]  O. Lingjaerde,et al.  Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations , 1993, Acta psychiatrica Scandinavica.

[7]  G. Mannens,et al.  Absorption, metabolism, and excretion of risperidone in humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[8]  A. Peer,et al.  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects , 1993, Clinical pharmacology and therapeutics.

[9]  C. Rhee,et al.  Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. , 1993, Yonsei medical journal.

[10]  J. Levron,et al.  Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. , 1993, Journal of chromatography.

[11]  A. Czyrak,et al.  Pharmacological Effects of Zotepine and other Antipsychotics on the Central 5-HT2 Receptors , 1993, Pharmacopsychiatry.

[12]  W. Maier,et al.  Risperidone in the Treatment of Disorders with a combined Psychotic and Depressive Syndrome - A Functional Approach , 1992, Pharmacopsychiatry.

[13]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.

[14]  C. Bowden,et al.  Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. , 1992, The Journal of pharmacology and experimental therapeutics.

[15]  J. Peuskens,et al.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study , 1992, Acta psychiatrica Scandinavica.

[16]  S. Taylor,et al.  Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment. , 1992, Archives of general psychiatry.

[17]  E. Richelson,et al.  Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. , 1992, The Journal of pharmacology and experimental therapeutics.

[18]  H. Möller,et al.  Efficacy and Tolerability of a New Antipsychotic Compound (Risperidone): Results of a Pilot Study , 1991, Pharmacopsychiatry.

[19]  H. Silver,et al.  Treatment of chronic schizophrenia with cyproheptadine: A double-blind placebo-controlled study , 1991, Biological Psychiatry.

[20]  R. Spealman,et al.  Behavioral effects of D1 and D2 dopamine receptor antagonists in squirrel monkeys. , 1991, The Journal of pharmacology and experimental therapeutics.

[21]  M. Koulu,et al.  Neurochemical effects of chronic co-administration of ritanserin and haloperidol: comparison with clozapine effects. , 1990, European journal of pharmacology.

[22]  H. Silver,et al.  Postural hypotension in chronically medicated schizophrenics. , 1990, The Journal of clinical psychiatry.

[23]  G. Meco,et al.  Combined serotonin‐5‐HT2 and dopamine‐D2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766) , 1990 .

[24]  P. Janssen,et al.  Pilot Clinical Investigation of Risperidone in the Treatment of Psychotic Patients , 1990, Pharmacopsychiatry.

[25]  C. Saller,et al.  5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. , 1990, The Journal of pharmacology and experimental therapeutics.

[26]  C. Dugovic,et al.  Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat , 1989, Neuropharmacology.

[27]  J. Leysen,et al.  Receptor occupancy by ritanserin and risperidone measured using ex vivo autaradiography , 1989, Brain Research.

[28]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[29]  Y. Gelders.  Thymosthenic Agents, A Novel Approach in the Treatment of Schizophrenia , 1989, British Journal of Psychiatry.

[30]  H. Silver,et al.  Neuroendocrine responses in chronic schizophrenia Evidence for serotonergic dysfunction , 1988, Schizophrenia Research.

[31]  J. C. Stoof,et al.  Biochemical profile of risperidone, a new antipsychotic. , 1988, The Journal of pharmacology and experimental therapeutics.

[32]  S. Heylen,et al.  Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration. , 1988, Acta psychiatrica Belgica.

[33]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[34]  C. Idzikowski,et al.  5-Hydroxytryptamine-2 antagonist increases human slow wave sleep , 1986, Brain Research.

[35]  J. Tuomisto,et al.  Neurotransmitter regulation of anterior pituitary hormones. , 1985, Pharmacological reviews.

[36]  E. Richelson.  Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. , 1984, The Journal of clinical psychiatry.

[37]  J. Leysen,et al.  The pharmacological and biochemical basis of neuroleptic treatment in schizophrenia , 1982, Pharmaceutisch Weekblad.

[38]  R J Wyatt,et al.  Increased whole blood serotonin concentrations in chronic schizophrenic patients. , 1981, Archives of general psychiatry.

[39]  Sakutaro Tadokoro,et al.  Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses , 1981, Pharmacology Biochemistry and Behavior.

[40]  F. Quitkin,et al.  Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. , 1978, Archives of general psychiatry.

[41]  C. Niemegeers,et al.  Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats. , 1977, Archives internationales de pharmacodynamie et de therapie.

[42]  A. Bravo-Mehmedbašić.  Risperidone in the treatment of schizophrenia. , 2011, Medicinski arhiv.

[43]  D. Casey.  Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates , 2005, Psychopharmacology.

[44]  T. Meert,et al.  Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats , 2004, Psychopharmacology.

[45]  P. Janssen,et al.  Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone , 2004, Psychopharmacology.

[46]  H. Meltzer,et al.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia , 2004, Psychopharmacology.

[47]  K. Brøsen,et al.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism , 2004, European Journal of Clinical Pharmacology.

[48]  F. Müller-Spahn.  RISPERIDONE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS: AN INTERNATIONAL DOUBLE‐BLIND PARALLEL‐GROUP STUDY VERSUS HALOPERIDOL. , 1992, Clinical neuropharmacology.

[49]  G. Reynolds.  Developments in the drug treatment of schizophrenia. , 1992, Trends in pharmacological sciences.

[50]  A. Megens,et al.  Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. , 1992, The Journal of pharmacology and experimental therapeutics.

[51]  G. Meco,et al.  Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo , 1989 .

[52]  T. Meert,et al.  Partial and complete blockade of 5‐hydroxytrytophan (5‐HTP)‐induced head twitches in the rat: A study of ritanserin (R 55 667), risperidone (R 64 766), and related compounds , 1988 .

[53]  D. Kupfer,et al.  Electroencephalographic sleep in young, never-medicated schizophrenics. A comparison with delusional and nondelusional depressives and with healthy controls. , 1987, Archives of general psychiatry.

[54]  S. Marini,et al.  Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent , 1986 .

[55]  R. Hitzemann,et al.  Down-regulation of central dopamine receptors in schizophrenia. , 1985, The American journal of psychiatry.

[56]  T. van Putten.  Why do schizophrenic patients refuse to take their drugs? , 1974, Archives of general psychiatry.